Zogenix, Inc., a pharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system disorders and pain. The company's principal commercial product includes SUMAVEL DosePro (sumatriptan injection) Needle-free Delivery System for the acute treatment of migraine and cluster headache. It also offers ZX002, a novel, oral, single-entity controlled-release formulation of hydrocodone that is in Phase 3 clinical trials for the treatment of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. In December 2010, the company received approval from the Danish Medicines Agency of Denmark for the Marketing Authorization Application for SUMAVEL DosePro Needle-Free Delivery System. Zogenix, Inc. was founded in 2006 and is based in San Diego, California.